ClinConnect ClinConnect Logo
Search / Trial NCT06249334

Whole-Body Electrical Stimulation in Patients Undergoing Lung Transplantation

Launched by FEDERAL UNIVERSITY OF HEALTH SCIENCE OF PORTO ALEGRE · Feb 6, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Lung Transplantation Electric Stimulation Randomized Controlled Trial

ClinConnect Summary

This clinical trial is studying the effects of a treatment called whole-body electrical stimulation (WB-EMS) on patients who are undergoing lung transplantation. The goal is to see if adding WB-EMS to regular physiotherapy can help patients recover better after their surgery. Patients will be placed into two groups: one group will receive the usual physiotherapy, while the other group will get both physiotherapy and WB-EMS every day until they leave the hospital. Researchers will assess patients at several points: before the lung transplant, after they have been taken off the ventilator, during the treatment, and when they are ready to go home.

To be eligible for this trial, patients must be adults aged 18 and older who are set to have a lung transplant and are stable enough to start rehabilitation within a week after their surgery. However, certain conditions, like severe heart problems or infections, may prevent someone from participating. If someone joins the trial, they can expect regular check-ins and treatments designed to support their recovery journey. It's important to know that this study is not yet recruiting participants, so it will start in the near future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients undergoing unilateral or bilateral lung transplantation;
  • Admitted to the intensive care unit and without invasive ventilatory support;
  • Hemodynamically stable;
  • Time less than or equal to 7 days between lung transplantation and the beginning of rehabilitation protocols.
  • Exclusion Criteria:
  • Patients with severe psychomotor agitation;
  • Recent acute myocardial infarction (24 hours) and / or uncontrolled arrhythmias;
  • Temporary transcutaneous pacemaker;
  • Stroke after lung transplantation;
  • Decompensated heart failure;
  • Uncontrolled hypertension (systolic blood pressure \> 230 mmHg and diastolic blood pressure \> 120 mmHg) or mean arterial pressure \<60 mmHg;
  • Patients who present important hemodynamic changes during training;
  • Peripheral vascular changes in the lower limbs such as untreated deep vein thrombosis;
  • In a feverish state;
  • Patients with epidermal lesions on the thighs that make it impossible to place self-adhesive electrodes for electrical stimulation;
  • Patients with acute renal failure.

About Federal University Of Health Science Of Porto Alegre

The Federal University of Health Science of Porto Alegre (UFCSPA) is a distinguished academic institution in Brazil, dedicated to advancing healthcare education, research, and clinical practice. Renowned for its commitment to excellence in medical and health sciences, UFCSPA plays a pivotal role in fostering innovation through rigorous clinical trials and collaborative research initiatives. The university's research programs are designed to address pressing health challenges, enhance patient care, and contribute to the scientific community, ensuring that findings translate into meaningful health solutions. With a multidisciplinary approach and a focus on ethical standards, UFCSPA is at the forefront of improving health outcomes both locally and globally.

Locations

Porto Alegre, Rio Grande Do Sul (Rs), Brazil

Porto Alegre, , Brazil

Patients applied

0 patients applied

Trial Officials

Jociane Schardong, PhD

Principal Investigator

Federal University of Health Sciences of Porto Alegre

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported